<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484731</url>
  </required_header>
  <id_info>
    <org_study_id>585</org_study_id>
    <secondary_id>ISRCTN pending</secondary_id>
    <nct_id>NCT00484731</nct_id>
  </id_info>
  <brief_title>Effect of Intraoperative Infiltration With Bupivacain on the Development of Chronic Pain After Inguinal Hernia Repair</brief_title>
  <official_title>Investigating the Effect of Intra-operative Infiltration With Local Anaesthesia on the Development of Chronic Postoperative Pain After Inguinal Hernia Repair. A Randomized Placebo Controlled Triple Blinded and Group Sequential Study Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of intraoperative infiltration of the operation site with bupivacain on the&#xD;
      development of chronic pain is the object of our trial. We hypothesize that the occurrence of&#xD;
      chronic pain in the goup of patients receiving the infiltration will be 50% less than in the&#xD;
      placebo group receiving normal saline. The study is a randomized controlled triple blinded&#xD;
      trial with a sequential study design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      264 patients scheduled for an inguinal hernia repair using one of three procedures&#xD;
      (Lichtenstein, Barwell and TEP = total extraperitoneal hernioplasty) are being randomly&#xD;
      allocated intra-operatively into two groups. Group I patients receive a local injection of&#xD;
      20ml Carbostesin® 0.25% at the end of the operation according to a standardised procedure.&#xD;
      Group II patients get a 20 ml placebo (0.9% Saline) injection. We use pre-filled identically&#xD;
      looking syringes for blinded injection, i.e. the patient, the surgeon and the examinator who&#xD;
      performs the postoperative clinical follow-ups remain unaware of group allocation. The&#xD;
      primary outcome of the study is the occurrence of developing chronic pain (defined as&#xD;
      persistent pain at 3 months FU) measured by VAS and Pain Matcher® device (Cefar Medical AB,&#xD;
      Lund, Sweden).&#xD;
&#xD;
      In addition to a sample size re-evaluation three interim analyses are planned after 120, 180&#xD;
      and 240 patients had finished their 3-months follow-up to allow for early study termination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of chronic pain</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Pain:Pain Matcher®,VAS;Areas of hyperalgesia,hypaesthesia Hospitalization:Length of stay (days) ASA-Classification Beginning of mobilisation (days) Return to work or normal activity (days and %) Quality of life (SF36)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Injection with Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection with Saline instead of Bupivacain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection with Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection with Bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infiltration with Saline</intervention_name>
    <description>Infiltration with Bupivacaine according to protocol</description>
    <arm_group_label>Injection with Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infiltration with Bupivacaine</intervention_name>
    <arm_group_label>Injection with Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years) with primary or recurrent single or double sided&#xD;
             symptomatic but not incarcerated inguinal hernias with an elective hernia repair are&#xD;
             included.&#xD;
&#xD;
          -  No other interventions (i.e. umbilical hernia) are allowed.&#xD;
&#xD;
          -  Written informed consent needs to be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with legal incompetence,&#xD;
&#xD;
          -  Pregnant and nursing women,&#xD;
&#xD;
          -  Patients with presence or history of active malignancy or systemic diseases,&#xD;
&#xD;
          -  Under immunosuppressive treatment,&#xD;
&#xD;
          -  With systemic or severe local inflammation or infection,&#xD;
&#xD;
          -  With wound healing disorders and with physical or mental incapacity, which makes it&#xD;
             impossible to obtain informed consent are excluded.&#xD;
&#xD;
          -  As pacemakers interfere with the electrical stimulation of the Pain Matcher® and vice&#xD;
             versa patients with pacemakers or other implanted electrical devices were also&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürg Metzger, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 7, 2007</study_first_submitted>
  <study_first_submitted_qc>June 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2007</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

